×
About 1,175 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  571 results

Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuxi...
https://doi.org/10.1053/j.seminhematol.2021.02.006
Seminars in Hematology; Nizamuddin I, Galvez C et. al.

Apr 28th, 2021 - Peripheral T-cell lymphomas (PTCL) are rare lymphoproliferative disorders with poor outcomes and high rates of relapse. Incidence varies although the most common subtypes include PTCL-not-otherwise specified, anaplastic large cell lymphoma, and an...

Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper C...
https://doi.org/10.1053/j.seminhematol.2021.03.001
Seminars in Hematology; Ma H, O'Connor OA et. al.

Apr 28th, 2021 - Despite the remarkable improvements in the treatment and outcome of patients with aggressive B-cell lymphoma, the peripheral T-cell lymphomas (PTCL) continue to carry a poor prognosis with the presently available treatment options. The PTCL are ve...

Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphom...
https://doi.org/10.1016/j.clml.2021.03.002
Clinical Lymphoma, Myeloma & Leukemia; Nguyen PN, Tran NTB et. al.

Apr 14th, 2021 - Studies have recently shown that RHOA mutations play a crucial role in angioimmunoblastic T-cell lymphoma (AITL) pathogenesis. We aimed to pool data from these studies to provide a comparison of clinicopathological features between the RHOA mutant...

Conditional survival and hazards of death for peripheral T-cell lymphomas.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064157
Aging Gao H, Ji X et. al.

Apr 5th, 2021 - Typically, peripheral T-cell lymphoma (PTCLs) prognosis is estimated using overall survival before treatment. However, these estimates cannot show how prognosis evolves with the changing hazard rate over time. Patients (n = 650) with newly diagnos...

see more →

Clinicaltrials.gov  585 results

Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuxi...
https://doi.org/10.1053/j.seminhematol.2021.02.006
Seminars in Hematology; Nizamuddin I, Galvez C et. al.

Apr 28th, 2021 - Peripheral T-cell lymphomas (PTCL) are rare lymphoproliferative disorders with poor outcomes and high rates of relapse. Incidence varies although the most common subtypes include PTCL-not-otherwise specified, anaplastic large cell lymphoma, and an...

Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper C...
https://doi.org/10.1053/j.seminhematol.2021.03.001
Seminars in Hematology; Ma H, O'Connor OA et. al.

Apr 28th, 2021 - Despite the remarkable improvements in the treatment and outcome of patients with aggressive B-cell lymphoma, the peripheral T-cell lymphomas (PTCL) continue to carry a poor prognosis with the presently available treatment options. The PTCL are ve...

Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphom...
https://doi.org/10.1016/j.clml.2021.03.002
Clinical Lymphoma, Myeloma & Leukemia; Nguyen PN, Tran NTB et. al.

Apr 14th, 2021 - Studies have recently shown that RHOA mutations play a crucial role in angioimmunoblastic T-cell lymphoma (AITL) pathogenesis. We aimed to pool data from these studies to provide a comparison of clinicopathological features between the RHOA mutant...

Conditional survival and hazards of death for peripheral T-cell lymphomas.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064157
Aging Gao H, Ji X et. al.

Apr 5th, 2021 - Typically, peripheral T-cell lymphoma (PTCLs) prognosis is estimated using overall survival before treatment. However, these estimates cannot show how prognosis evolves with the changing hazard rate over time. Patients (n = 650) with newly diagnos...

see more →

News  19 results

Angioimmunoblastic T-cell Lymphoma: Patient Characteristics and Survival Outcomes
https://www.mdedge.com/fedprac/avaho/article/207820/lymphoma-plasma-cell-disorders/angioimmunoblastic-t-cell-lymphoma?channel=53
Ermann DA, Vardell VA et. al.

Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
https://www.mdedge.com/hematology-oncology/article/193975/lymphoma-plasma-cell-disorders/cerdulatinib-yields-encouraging?channel=39313
Jennifer Smith

Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.

Combo emerges as bridge to transplant in rel/ref PTCL
https://www.mdedge.com/hematology-oncology/article/193912/lymphoma-plasma-cell-disorders/combo-emerges-bridge-transplant/page/0/1?channel=39313

Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.

Four-drug combo shows durable responses in relapsed/refractory lymphomas
https://www.mdedge.com/hematology-oncology/article/193002/t-cell-lymphomas/four-drug-combo-shows-durable-responses-relapsed
Jennifer Smith

Jan 19th, 2019 - LA JOLLA, CALIF. — Results of a phase 1 trial suggest a four-drug combination can produce durable responses in patients with relapsed or refractory T- and B-cell lymphomas.

see more →